Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Amneal Pharmaceuticals

30/07/2026 17:13

Amneal Pharmaceuticals Inc AMRX.OQ reported quarterly adjusted earnings of 30 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 25 cents.  The mean expectation of five analysts for the quarter was for earnings of 22 cents per share. Wall Street expected results to range from 20 cents to 25 cents per share.
Revenue rose 9.9% to $796.20 million from a year ago; analysts expected $768.21 million. 
Amneal Pharmaceuticals Inc's reported EPS for the quarter was 18 cents​.
The company reported quarterly net income of $69.61 million.
Amneal Pharmaceuticals Inc shares had risen by 10.3% this quarter and gained 51.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 3.7% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Amneal Pharmaceuticals Inc is $19.00, about 0.5% below its last closing price of $19.10
This summary was machine generated from LSEG data July 30 at 04:13 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.22
0.30
Beat
Mar. 31 2026 
0.17
0.27
Beat
Dec. 31 2025 
0.18
0.21
Beat
Sep. 30 2025 
0.14
0.17
Beat